Our overall goal is to improve patient outcomes by facilitating widespread clinical adoption of pH technology to advance diagnostics and treatment of various diseases.
Our business strategy is to develop particular applications either independently or through partnership/collaboration.
Cybrexa Therapeutics holds exclusive rights for the development of therapeutic agents based on use of pH-sensitive peptides, pHLIP®, for targeting and delivery of some DNA repair inhibitors and some cytotoxic molecules.
Integral to our business strategy is the proliferation of our technology via sublicensing deals with established companies and uniquely-positioned startups. Please contact us